Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model

远交兔热病模型中疫苗诱导的可调节保护的相关性

基本信息

  • 批准号:
    9077642
  • 负责人:
  • 金额:
    $ 78.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-02-15 至 2021-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Francisella tularensis is the causitive agent of tularemia, a severe zoonotic disease in humans with fatality rates exceeding 30% in untreated subjects. Infection following inhalation causes the most severe form of disease and combind with its high virulence and history of weaponization makes this pathogen a concern for use as a biological weapon. Development of a vaccine that protects against aerosol infection is a priority. We have engineered a series of live attenuated vaccine candidates based on the highly virulent Schu S4 strain that exhibit a range of protective capacities in the mouse and rabbit models of respiratory challenge. Our studies have confirmed that rabbits are an excellent model of human pneumonic tularemia and a highly relevant model for evaluating tularemia vaccines as they display similar resistance to attenuated strains and susceptibility to virulent strains as humans. We hypothesize that the outbred human-relevant, rabbit model will allow us to identify correlates of protection using the collection of vaccine strains that confer a range (0% to 83%) of protective efficacies against lethal aerosol challenge. This grant seeks to understand the mechanism(s) underlying this protection. Our hypothesis is that effective vaccination in the rabbit model is a product of i) induction of particular, Ag-specific responses and/or ii) the immunogen's persistence and immuno-stimulatory properties. The first aim will identify the bacterial Ag(s) recognized specifically by protective immune responses. The second aim will explore the humoral and cellular immune response as well as the role of persistence and immune stimulation by F. tularensis derivatives in protection against challenge. The third aim will evaluate the efficacy of a subunit vaccine and an optimized live attenuated vaccine against inhalation of F. tularensis. The information gained under this proposal will expand our understanding of the humoral and cellular immune response to tularemia vaccines, the importance of these responses in protection against tularemia in the rabbit and the relevance to protection in humans.
 描述(由申请方提供):土拉热弗朗西斯菌是土拉菌病的致病因子,土拉菌病是一种严重的人畜共患病,未经治疗的受试者死亡率超过30%。吸入后的感染引起最严重的疾病,加上其高毒性和武器化历史,使这种病原体成为一种令人关切的生物武器。研制一种预防气溶胶感染的疫苗是当务之急。我们已经设计了一系列基于高毒力Schu S4菌株的减毒活疫苗候选物,其在小鼠和兔呼吸道攻击模型中表现出一系列保护能力。我们的研究已经证实,兔是人肺炎土拉菌病的优良模型,也是评价土拉菌病疫苗的高度相关模型,因为它们显示出与人相似的对减毒株的抗性和对强毒株的敏感性。我们假设远系繁殖的人类相关的兔模型将允许我们使用疫苗株的集合来鉴定保护的相关性,所述疫苗株赋予范围(0%至83%)的保护性。 对致命气溶胶攻击的效力。本补助金旨在了解这种保护的机制。我们的假设是,兔模型中的有效疫苗接种是i)特定Ag特异性应答的诱导和/或ii)免疫原的持久性和免疫刺激特性的产物。第一个目标是鉴定保护性免疫应答特异性识别的细菌Ag。第二个目的是探讨F.土拉菌衍生物在对抗挑战的保护中的作用。第三个目标是评估亚单位疫苗和优化的减毒活疫苗对吸入性F。土拉热。根据该提案获得的信息将扩大我们对兔热病疫苗的体液和细胞免疫应答的理解,这些应答在兔兔热病保护中的重要性以及与人类保护的相关性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eileen M. Barry其他文献

Characterization of emShigella flexneri/em serotype 6 strains from geographically diverse low- and middle-income countries
来自不同地理区域的中低收入国家的 em 弗氏志贺菌 6 型菌株的特征描述
  • DOI:
    10.1128/mbio.02210-24
  • 发表时间:
    2024-11-29
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Caitlin E. Gabor;Charlotte E. Chong;Jose M. Lemme-Dumit;Tracy H. Hazen;Kate S. Baker;Karen L. Kotloff;Irene N. Kasumba;Sharon M. Tennant;Henry Badji;M. Jahangir Hossain;Richard Omore;Benjamin Ochieng;Alex O. Awuor;Billy Ogwel;Jane Juma;Eileen M. Barry;David A. Rasko
  • 通讯作者:
    David A. Rasko
The 2022 Vaccines Against <em>Shigella</em> and Enterotoxigenic <em>Escherichia coli</em> (VASE) Conference: Summary of abstract-based presentations
  • DOI:
    10.1016/j.vaccine.2023.11.031
  • 发表时间:
    2024-03-07
  • 期刊:
  • 影响因子:
  • 作者:
    Soumalya Banerjee;Eileen M. Barry;Shahida Baqar;A. Louis Bourgeois;Joseph J. Campo;Robert K.M. Choy;Subhra Chakraborty;Allison Clifford;Carolyn Deal;Marcus Estrada;James Fleckenstein;Mateusz Hasso-Agopsowicz;William Hausdorff;Ibrahim Khalil;Nicole Maier;Cynthia Mubanga;James A. Platts-Mills;Chad Porter;Firadausi Qadri;Michelo Simuyandi
  • 通讯作者:
    Michelo Simuyandi
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
志贺菌疫苗的临床试验:在漫长而艰难的道路上前进两步后退一步
  • DOI:
    10.1038/nrmicro1662
  • 发表时间:
    2007-07-01
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Myron M. Levine;Karen L. Kotloff;Eileen M. Barry;Marcela F. Pasetti;Marcelo B. Sztein
  • 通讯作者:
    Marcelo B. Sztein
Genomic, transcriptomic, and phenotypic differences among archetype emShigella flexneri/em strains of serotypes 2a, 3a, and 6
血清型 2a、3a 和 6 的原型 em 福氏志贺氏菌菌株之间的基因组、转录组和表型差异
  • DOI:
    10.1128/msphere.00408-23
  • 发表时间:
    2023-11-28
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Caitlin E. Gabor;Tracy H. Hazen;BreOnna C. Delaine-Elias;David A. Rasko;Eileen M. Barry;Vincent B. Young
  • 通讯作者:
    Vincent B. Young

Eileen M. Barry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eileen M. Barry', 18)}}的其他基金

Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 78.98万
  • 项目类别:
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.
对表达产肠毒素大肠杆菌抗原(CVD 1208S-122 菌株)的福氏志贺氏菌 2a 活载体进行初步临床评估。
  • 批准号:
    10407441
  • 财政年份:
    2020
  • 资助金额:
    $ 78.98万
  • 项目类别:
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.
对表达产肠毒素大肠杆菌抗原(CVD 1208S-122 菌株)的福氏志贺氏菌 2a 活载体进行初步临床评估。
  • 批准号:
    10212188
  • 财政年份:
    2020
  • 资助金额:
    $ 78.98万
  • 项目类别:
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease
预防 MDR 志贺氏菌和 ETEC 疾病的扩展多价疫苗
  • 批准号:
    10584477
  • 财政年份:
    2019
  • 资助金额:
    $ 78.98万
  • 项目类别:
An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease
预防 MDR 志贺氏菌和 ETEC 疾病的扩展多价疫苗
  • 批准号:
    10364710
  • 财政年份:
    2019
  • 资助金额:
    $ 78.98万
  • 项目类别:
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122
良好生产规范主细胞和工作细胞库以及表达产肠毒素大肠杆菌抗原的福氏志贺氏菌 2a 活载体原型 GMP 中试批次,CVD 1208S 122
  • 批准号:
    9363198
  • 财政年份:
    2017
  • 资助金额:
    $ 78.98万
  • 项目类别:
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development
模拟肠类共培养物中志贺氏菌与先天细胞的相互作用,为疫苗开发提供信息
  • 批准号:
    10427393
  • 财政年份:
    2016
  • 资助金额:
    $ 78.98万
  • 项目类别:
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development
模拟肠类共培养物中志贺氏菌与先天细胞的相互作用,为疫苗开发提供信息
  • 批准号:
    10745566
  • 财政年份:
    2016
  • 资助金额:
    $ 78.98万
  • 项目类别:
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development
模拟肠类共培养物中志贺氏菌与先天细胞的相互作用,为疫苗开发提供信息
  • 批准号:
    10190303
  • 财政年份:
    2016
  • 资助金额:
    $ 78.98万
  • 项目类别:
Modeling Shigella Interaction with Innate Cells in Enteroid Co-Cultures to Inform Vaccine Development
模拟肠类共培养物中志贺氏菌与先天细胞的相互作用,为疫苗开发提供信息
  • 批准号:
    10686834
  • 财政年份:
    2016
  • 资助金额:
    $ 78.98万
  • 项目类别:

相似海外基金

AEROSOLS
气雾剂
  • 批准号:
    10101317
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    EU-Funded
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
  • 批准号:
    10092043
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
  • 批准号:
    2332007
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000021/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000358/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
  • 批准号:
    DP240100389
  • 财政年份:
    2024
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Discovery Projects
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
  • 批准号:
    2326096
  • 财政年份:
    2023
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Standard Grant
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
  • 批准号:
    83001507
  • 财政年份:
    2023
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
  • 批准号:
    ST/X001091/1
  • 财政年份:
    2023
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Research Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
  • 批准号:
    10080253
  • 财政年份:
    2023
  • 资助金额:
    $ 78.98万
  • 项目类别:
    Small Business Research Initiative
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了